Zhitong Finance App News, Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., an innovative pharmaceutical holding subsidiary of the company, is carrying out a randomized, double-blind, placebo-controlled clinical trial (GST-peak-triple) to evaluate the safety and efficacy of the triple full oral administration plan (GST-HG141+GST-HG131+ NAS nucleoside (acid)) in patients with chronic hepatitis B virus (GST-Peak-Triple). The first trial participants were successfully enrolled and administered.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.